ISSN 2816-573X

REVIEW ARTICLE

Precision in Practice: Nanotechnology and Targeted Therapies for Personalized Care

Ashutosh Sengar*

Sengar A. Precision in Practice: Nanotechnology and Targeted Therapies for Personalized Care. Int J Adv Nano Comput Anal. 2024;3(2):56-67.

Abstract

Customization of medicine has made healthcare even more personalized, enhancing therapeutical efficiency with low adverse effects. It can be achieved through an innovative tool that has reached unprecedented abilities through the process of nanotechnology in targeted drug delivery, advanced diagnostics, and therapeutic systems. This makes a review on the integration of nanotechnology with personalized medicine-including historical considerations towards applications in today's contexts up to future perspectives.

The targeting of diseased tissues has proven to be tremendous, considering a combination of both passive and active targeting mechanisms that nanospheres assume the form of liposomes, dendrimers, or polymeric micelles. Quantum dots and nanosensors have revolutionized the area of diagnostics, enabling detection at an earliest possible stage with real-time monitoring, changing patient care forever. Theranostic platforms, integrating therapeutic agents with diagnostic tools, really reveal the dynamic ability to customize treatments.

Despite these strides forward, the critical problems to be overcome are those related to biological complexity, barriers caused by regulation, and eventual long-term toxicities. Biocompatible biodegradable nanocarrier research and responsive system explorations will help move such applications forward in a positive fashion toward better and safer designs. The joining of wearable nanotechnology to a nanoparticle-enabled gene delivery system is probably going to move standards of care.

This review outlines the crucial role nanotechnology is playing in moving personalized medicine forward, from bridging diagnosis to therapy and filling the gap of heterogeneity in disease. But a lot more is to come because it holds promise for a revolution in healthcare ever more precise, adaptable, and patient-centered with innovation and interdisciplinary collaboration continuing.

Key Words: *Theranostics; Diagnostics; Quantum dots; Biodegradable nanocarriers; Personalized medicine*

Assistant Professor, Smt. Vidyawati College of Pharmacy, Jhansi, Uttar Pradesh, India

Corresponding author: Ashutosh Sengar, Assistant Professor, Smt. Vidyawati College of Pharmacy, Jhansi, Uttar Pradesh, India, Email: ashutoshsengar26567@gmail.com

Received: December 13, 2024, Accepted: December 20, 2024, Published: December 30, 2024

Introduction

Personalized medicine is the new paradigm in health care where prescription of treatments considers individual patient-specific genetic, environmental, and lifestyle characteristics. This offers more effective treatment with fewer side effects than the traditional "one-size-fits-all" approach. Advances in genomic technologies and molecular profiling have been key to this end, as they have made it possible to determine patient-specific biomarkers and pathways for treatment [1-4].

Nanotechnology has now become a key to an enabling tool in personalized medicine both in therapeutics and diagnostics. The nanoscale of nanotechnology makes it possible to prepare nanoparticles with extraordinary physicochemical properties such as extremely large surface-area-to-volume ratios and functionalities that can be designed. Thus, these nanoparticles may serve as useful vectors for targeted drug delivery, imaging, and even theranostic purposes.

Nanocarriers which include liposomes, dendrimers, and polymeric nanoparticles, have been used in the oncological field as it has facilitated delivering chemotherapeutic agents right at the target site. Here nanocarriers are used upon the concept of EPR effect, hence eliminating the systemic toxicity and maximizing the therapy potential [3-6]. In Cardiovascular, Neurological, and Infections, it has become one of the important precursors that can allow early diagnosis and individualized treatments [7-10].

This could provide new avenues toward answering the problem of heterogeneity in the disease, as this often leads to a targeted and adaptive therapy for patients diagnosed with cancer diseases [11,12].

This article delineates how nanotechnology works together with personalized medicine so that through this combination, it provides the solutions to health care. By using nanotechnology, diseases that are very heterogeneous with therapy resistance might not pose major challenges in managing modern medicines [2,7].

Personalized Medicine and Nanotechnology

Evolution, challenges, and applications of nanotechnology in precision care

Personalized medicine is a response to the failure of generalized, traditional treatments to address patient needs. With the advancement of genomics and proteomics, personalized medicine can target specific molecular pathways for every patient. The uniqueness of nanotechnology has also significantly contributed to the advancement of personalized medicine by offering drug delivery, diagnostics, and theranostics with great precision [6,10].

One of the more important applications of nanotechnology is in drug delivery systems. Nanoparticles, especially liposomes, dendrimers, and polymeric micelles, enable targeted drug delivery into diseased tissues with the least damage to healthy cells. Nanoparticle delivery systems are increasingly being used for enhancing drug bioavailability and specificity, particularly in the treatment of cancer [3,7].

These NPs can exploit the EPR effect selectively to localize drugs at tumor sites by improving therapeutic efficacy while significantly reducing systemic toxicity [6,7]. For instance, Doxil is one of the liposomal preparations of doxorubicin for clinical applications in specific therapies for cancers with significantly reduced levels of cardiotoxicity in patients [8].

Despite all these, several challenges lie ahead.

The biological complexity of disease, such as cancer, results in heterogeneous drug response even when nanotechnology is involved. Issues of great concern are the biocompatibility and long-term toxicity of the nanoparticles. Regulatory hurdles further delay the bench-to-bedside translation of nanomedicine [9,10]. These will require great interdisciplinary collaborations between material scientists, clinicians, and regulatory agencies.

Diagnosis also requires nanotechnology equally. Quantum dots and magnetic nanoparticles have advanced the imaging modality to such an extent with better resolution and real-time monitoring of disease progression [11,12]. Similarly, the personal care horizon has changed with the arrival of theranostic platforms, which integrate diagnosis and therapy into one system. Such systems allow real-time feedback regarding the efficacy of the treatment so that clinicians may adapt the therapeutic strategies in real-time [13].

The heterogeneity of solid tumors poses significant challenges for the delivery of effective nanomedicine and calls for innovative approaches to increase penetration and retention [14].

The delivery of nanomedicine to solid tumors faces a barrier of biological barriers such as dense stroma and poor vascularization that prevent efficient drug delivery [15].

This is a new direction for health care. The development of nanotechnology has allowed precision in interventions, tailored to a specific patient and thus addressing heterogeneity in disease; nanotechnology is leading the future in precision care (Table 1) [16,17].

Targeted Drug Delivery with Nanotechnology

Key systems and strategies in nanoparticle-mediated therapies

Nanoparticle-based drug delivery systems have changed targeted therapies through the improvement of bioavailability, reduction in systemic toxicity, and increased therapeutic efficacy. These systems rely on specific nanoscale properties to deliver drugs directly to diseased tissues, avoiding off-target effects. Among all these systems, it is liposomes, dendrimers, and polymeric nanoparticles that lead nanomedicine [17-19].

Liposomes are very useful pharmaceutical carriers that offer versatile platforms to encapsulate either hydrophilic or hydrophobic drugs, reducing systemic toxicity (Table 2) [6].

Nanoparticle-aptamer conjugates present a promising opportunity for cell-selective drug delivery in oncology. Dendrimers, highly branched structures resembling trees, allow exact drug loading; therefore, these are the perfect agents for delivery of anticancer agents [20-23].

On the contrary, polymeric nanoparticles have excellent stability with controlled drug release profiles. These nanoparticles may be designed to have a response toward stimuli that could be pH- or temperature-dependent to achieve localized drug release within the disease tissue. As for example, in vesicular nanocarriers, such as liposomes, the work on those continues to widen its horizon in precision care. For instance, great importance in respiratory health management [6,24].

The EPR effect has been the foundation for nanoparticle-based therapies where nanoparticles can be concentrated at the site of tumors since the leaky vasculature in tumors enhances the drug concentration at the targeted site [25,26]. The most common active targeting strategy involves ligand-functionalized nanoparticles that increase specificity through receptor binding to overexpressed receptors on tumor cells (Table 3) [27,28].

The shift from passive to active targeting in nanocarrier systems has marked a new era in cancer treatment, improving precision and minimizing off-target effects [12].

The styrene-co-maleic acid micellar system has demonstrated effectiveness in tumor-targeted drug delivery, leveraging the EPR effect to improve therapeutic outcomes [7].

While these systems have shown significant promise, challenges remain. Ensuring the biocompatibility and biodegradability of nanocarriers, overcoming multidrug resistance mechanisms, and achieving regulatory approval for clinical use are critical areas of ongoing research [15,16]. Despite these hurdles, the potential of nanoparticle-mediated therapies to transform targeted drug delivery is undeniable, offering new hope for patients with complex and resistant diseases [20,22].

Diagnostic and Theranostic Applications

Nanotechnology's role in diagnostics and combined therapeutic approaches

Nanotechnology has fundamentally transformed the landscape of diagnostics and theranostics, providing tools for early disease detection and simultaneous therapy. The convergence of therapeutic and diagnostic functionalities in theranostics represents a significant advancement in precision medicine, enabling real-time monitoring and adaptive treatment strategies (Table 4) [17,18].

TABLE 1

Nanotechnology in personalized medicine: evolution, applications, and challenges.

Aspect	Description	Examples/Remarks	References
Evolution of Personalized Medicine	Driven by advances in genomics and proteomics, focusing on patient-specific molecular pathways for precise interventions.	Nanotechnology contributes significantly through precise drug delivery and theranostics.	[10,11]
Drug Delivery Systems	Nanoparticles like liposomes, dendrimers, and polymeric micelles enable targeted drug delivery, enhancing drug bioavailability and specificity.	E.g., Doxil minimizes cardiotoxicity in cancer treatment.	[6-8]
EPR Effect	Enhanced Permeability and Retention (EPR) effect localizes drugs at tumor sites, improving therapeutic efficacy and reducing systemic toxicity.	Widely utilized in cancer nanomedicine.	[7,8]
Diagnostics	Quantum dots and magnetic nanoparticles improve imaging resolution and enable real-time monitoring of disease progression.	Facilitates dynamic assessment of disease states.	[11,12]
Theranostics	Combines therapeutic and diagnostic functions, providing real-time feedback on treatment efficacy and enabling adaptive strategies.	A pivotal innovation in precision care.	[13]
Challenges in Nanomedicine	Includes disease heterogeneity, biocompatibility, long-term toxicity concerns, and regulatory hurdles.	Requires interdisciplinary collaborations for effective solutions.	[9,10]

TABLE 2

Overview of liposomal nanocarriers in drug delivery.

Feature	Description	Examples/Remarks	References
Type	Liposomes, one of the earliest and widely utilized nanocarriers.	Recognized for their versatility in drug delivery.	[6,27]
Key Characteristics	Biocompatible and capable of encapsulating both hydrophilic and hydrophobic drugs.	Supports broad-spectrum drug delivery applications.	[6]
Surface Modifications	Incorporation of PEGylation enhances stability and prolongs circulation time in the bloodstream.	Improves pharmacokinetic profile and targeting efficiency.	[27,28]
Clinical Example	Doxil, a liposomal formulation of doxorubicin, reduces cardiotoxicity and targets tumors.	A notable success in clinical oncology applications.	[27,28]
Recent Advancements	Innovations in liposomal systems emphasize their role in targeted drug delivery.	Highlighted as a key approach in modern therapeutic research.	[1,29]

TABLE 3

Nanoparticle-based drug delivery systems in oncology.

Feature	Details	References
Nanoparticle-Aptamer Conjugates	Strategy for achieving cell-specific drug delivery in oncology, offering precise targeting for cancer therapies.	[29]
Dendrimers	Highly branched, tree-like structures with high drug-loading capacity, ideal for delivering anticancer agents.	[22,23]
Polymeric Nanoparticles	Engineered nanoparticles that respond to specific stimuli (e.g., pH or temperature) for controlled, localized drug release in diseased tissues.	[6,24]
Vesicular Nano-Carriers (Liposomal Systems)	Nano-carriers expanding in precision care, particularly in the management of respiratory health.	[6,24]

TABLE 4

Role of nanotechnology in diagnostics and theranostics.

Feature	Description	Examples/Remarks	References
Theranostics	Convergence of therapeutic and diagnostic functions, enhancing precision medicine. Enables real-time monitoring and adaptive treatment.	Combines diagnostics and therapy for advanced medical approaches.	[20,21]
Quantum Dots (QDs)	Nanoparticles with unique optical properties like brightness and photostability, used in imaging and biomarker detection.	Ideal for high-resolution cellular imaging and target tracking.	[17,18]
Magnetic Nanoparticles	Enhance contrast in magnetic resonance imaging (MRI) and enable targeted drug delivery.	Used for improving MRI imaging and targeted therapies.	[31,32]

With properties such as brightness and photostability, quantum dots (QDs) stand as promising diagnostic tools in the fields of imaging and biomarker detection. Such nanoparticles form the foundation of high-resolution cellular imaging and tracking targeted molecules in complex biological systems [17,18]. Magnetic nanoparticles are also potential candidates, with applications including enhancing contrast with MRI and targeting drug delivery capabilities.

The use of nanotechnology in forming the most exciting applications would be theranostic platforms. This system contains therapeutic agents and imaging components within one nanoparticle. It allows clinicians to monitor real-time drug release, target-site accumulation, and therapeutic response. An example is conjugated nanoparticles carrying anticancer drugs along with fluorescent markers, thereby enhancing treatment efficacy by performing tumor imaging and drug delivery at the same time [20,21].

Other avenues of improvement for nanocarriers are their application in theranostics for diseases that are not related to cancer. In cardiovascular and neurological disorders, multifunctional nanoparticles have shown great promise in targeting atherosclerotic plaques as well as in delivering neuroprotective agents [26,27]. Oral delivery platforms, such as mouth-dissolving films and effervescent-based platforms, have proven efficient in localized drug delivery for the treatment of specified therapeutic needs [6,28].

Despite all such innovations, challenges continue in nanoparticle stability, biocompatibility, and regulatory compliance. Scalability of the theranostic systems to mass-produce the system is also a challenge. Multidisciplinary approaches and robust clinical trials need to be addressed for such challenges [29,30].

Nanotechnology steadily redraws the map of diagnostics and theranostics, moving towards earlier points of detection, precision targeting, and adaptive therapies. Once more improved research comes about, it will fill more gaps between actual diagnosis and treatment steps, leading to tailored and effective health solutions [31,32].

Some other applications of nanotechnology in cancer go beyond therapy but focus on innovations towards trackable biomarkers along with therapeutic monitoring [33].

Multifunctional nanocarriers have emerged as potent tools in precision medicine by integrating diagnostic and therapeutic functionalities in one system [20].

Clinical Applications and Future Directions

Real-world applications and future prospects for nanomedicine in personalized care

Nanomedicine has well settled into clinical applications because it is able to overcome the longstanding challenges in therapeutic precision, drug delivery, and diagnostics. Some of the most significant among these developments include nanoparticle-mediated drug delivery systems and theranostic platforms that integrate therapeutic and diagnostic functions to achieve a holistic approach to personalized care (Figure 1) [12,22,26,33].



Figure 1) *Clinical application of nano medicine.*

Some of the best examples of the successful application of nanomedicine in the treatment of oncology are Doxil and albumin-bound paclitaxel, Abraxane. Formulations have relied on passive targeting mechanisms such as the EPR effect to concentrate chemotherapeutic agents at the tumor sites while sparing healthy tissues [25]. Active targeting strategies, such as nanoparticles conjugated with ligands, such as folic acid or HER2-specific antibodies, have further improved precision in drug delivery [30].

A more advanced platform for nanomedicine refers to the confluence of a therapeutic payload and a diagnostic imaging agent into one system of the nanoparticle. Such systems can track in real-time the delivery of drugs and therapeutic efficiency. They may provide personally tailored treatment plans that change their dynamic response based on patient conditions. For instance, quantum dots conjugated with anticancer agents offer real-time imaging of tumors combined with therapy, thus enhancing the accuracy of treatment [33]. Multifunctional nanoparticles are being increasingly applied to non-oncological conditions, such as targeting atherosclerotic plaques in cardiovascular disease and the delivery of neuroprotective drugs across the blood-brain barrier (Figure 2) [31,32].



Figure 2) *Nanotechnology in non-oncological diseases.*

Apart from the therapy applications, nanomedicine can be used as a challenge to innovate in patient surveillance and prevention. Biomarkers leading to the early diagnosis of diseases will be monitored in real-time through wearable nanotechnology devices incorporating nanosensors [32,33]. This is exactly what precision medicine calls for moving from reactive healthcare to proactive healthcare.

Nanomedicine, with immense potential for better patient care, brings in its wake more ethical and economic challenges in trying to achieve equal access for all. The cost implications of developing and manufacturing nanomedicine could prove too high for its accessibility in low-resource settings. There is a serious limitation to these novel treatments due to the price it carries and infrastructure for developing countries. Now, global initiatives like GHNI are trying to reduce these disparities by working to bring down the cost and accessibility of nanomedicine. This would make it easier for governments, non-profits, and the private sector to cooperate and bring nanomedicine to underprivileged groups.

Moreover, large-scale production of nanomedicines is economically challenging. Manufacturing processes are often complex and costly, requiring an enormous investment in technology and expertise. New models of production and distribution, including public-private partnerships and innovative manufacturing technologies, will be required to make these therapies affordable and accessible to a wide range of patients while maintaining high standards of quality and safety (Figure 3) [32,33].



Figure 3) *Future of nanomedicine: challenges and innovations.*

The future of nanomedicine lies in the resolution of the existing challenges, which include scalability of nanoparticles, regulatory approval, and the potential long-term toxicities. The stimuli-responsive nanoparticles, which release drugs in response to specific triggers such as pH or temperature, are designed to further improve therapeutic efficacy [12,31]. Biodegradable nanocarriers will also address issues related to long-term safety and environmental impact [32,33].

Expanded regulatory challenges in nanomedicine

It has been recognized that one of the main challenges against nanomedicine is the regulatory one. There are a lot of different applications of nanomaterials in healthcare and many new nanomaterials, which make nanomedicine very complex. There is already the framework of specific requirements and approaches to the safety, efficacy, and quality of nanomedicines from different global regulatory agencies, such as the FDA from the United States and EMA from Europe. However, these agencies exhibit vast differences in their appraisal of nanotechnology-based products, with the effect of affecting the rates at which new nanotherapies hit the shelves. These differences need to be addressed by the regulating agencies in order to expedite the timely introduction of nanomedicine in clinical settings and access globally [30,32].

Fda's approach: Rigorous safety and efficacy testing

The FDA is adopting a strict regulatory approach in nanomedicine. The new formulation would undergo extensive clinical trials after rigorous testing for safety and efficacy. The FDA has developed guidelines for the testing of risks posed by nanomaterials and ensured that the newly developed products are safe for human use. This encompasses in general pharmacokinetic studies tracking the fate of nanoparticles from their distribution to accumulation, long-term toxicity evaluation to look for potential adverse effects during the longer use periods. FDA is more concerned that nanomedicines should be safe enough for public consumption. These strict regulations are established for public health protection, but this can cause delay in approval, especially in innovative therapies where the needs of patients are urgent [30]. For example, in oncology, the FDA requires detailed studies on how nanocarriers, such as liposomes or polymeric nanoparticles, interact with tumour cells and normal tissues, which may extend the length of time required for approval considerably [30].

EMA's approach: Flexible regulatory pathways

On the contrary, it has a loose approach and regulation by EMA since it aims to move with all haste to get better therapeutic means to patients, especially drugs aimed to treat rare or life-threatening conditions. Adaptability of regulatory pathways - The EMA relies on the adaptive pathway for nanomedicine as well. Its approved nanomedicines have information culling from data resulting from early-stage clinical data with final-stage monitoring closely alongside safety checks. This adaptable process makes it possible for fast entry of innovative treatments without diluting its standards for

patient safety as these treatments remain under constant observation through clinical surveillance. The EMA approach does provide space for therapies, which otherwise may undergo lengthy waiting times in regulatory approval in more conventional frameworks. In the strict sense, the way of the EMA points towards those nanomedicines, whose approval would perhaps mean better access for the patient with breakthrough treatment options relating to diseases that feature unmet medical needs characterized as such, such as advanced cancers or neurological disorders [30]. This approach, however, brings post-market monitoring to the limelight in ensuring long-term safety.

The need for harmonization: Streamlining global approvals

The differences in regulatory frameworks of the FDA and the EMA indicate a bigger need for harmonization in global practices for regulation of nanomedicines. Though both agencies have a core focus on patient safety, both differ in terms of timelines regarding approval drugs and their procedure, thus impacting the access of nanomedicines into different regions. A single global approach to regulation or, at least the harmonization of FDA and EMA, would streamline the process and remove duplications within their procedures to gain headway into faster market entry into the many different regions. This also brings savings in cost on the side of the manufacturers, who may get covered various submissions by just one move. This would speed up the delivery of effective nanomedicines to patients globally, especially in regions where there is an urgent health need (Table 5) [31,32].

TABLE 5
Clinical applications of nanotechnology beyond oncology.

Application	Description	Examples/Remarks	References
Systemic Fungal Infections	Liposomal amphotericin B (AmBisome) reduces nephrotoxicity compared to traditional formulations.	A breakthrough in safer antifungal therapies.	[13]
mRNA Vaccines	Lipid nanoparticle-based mRNA vaccines have demonstrated scalability and effectiveness in addressing global challenges.	Successfully employed during the COVID-19 pandemic.	[25]
Autoimmune Diseases	siRNA-loaded nanoparticles silence pro-inflammatory cytokines, offering sustained and localized therapeutic effects in rheumatoid arthritis.	A novel approach for targeted immune modulation.	[33]

Where challenges lie, nanotechnology integration within clinics makes the way for customized healthcare as it delivers exacting, adaptable, and cost-effective health care [33].

Conclusion

Nanotechnology can greatly revolutionize the paradigm of personalizing medicine since it builds on the failures of the "one-size-fits-all" traditional approach. It allows for precision diagnostics, targeted therapies, and real-time monitoring, hence absolutely complementing the objective of personalized care. This review discusses the progress made in nanotechnology, its applications, problems, and future directions regarding the advancement of precision medicine.

This has been propelled forward by the special promise of nanotechnology both for targeted delivery of therapeutic agents and diagnostics. In this regard, there have been excellent performances by liposomes, dendrimers, and polymeric nanoparticles in effectively targeting diseased sites through low systemic toxicity with enhanced therapeutic efficacy. The basis for the EPR effect so far has remained intact as improvements for targeted delivery involved active approaches such as ligand-functionalized nanoparticles as well as nanoparticle aptamer conjugates.

Diagnostically, nanotechnology is transformative, and a quantum dot, magnetic nanoparticle, and nanosensor enable an unprecedented ability to detect diseases and monitor them. There exists unprecedented resolution in imaging diagnostics, where early diagnosis of preparation of personalized treatments become accessible. A theranostic platform that brings along the functionalities of both diagnosis and therapy signifies an unprecedented advance as it allows insight into efficacy in real-time and permits adaptive treatment.

Such achievements, however, still pose a set of problems. For instance, cancer, biological complexity, and heterogeneous patient responses indicate the need for more efficient and flexible nanotechnology approaches in treating such diseases. Other issues are specific regulatory matters, long-term toxicities, and scaling that may restrain more widespread acceptance of nanomedicine. Scientists have shown keen interest in the study of biodegradable and stimuli-responsive nanoparticles in overcoming such issues and facilitating safer clinical application.

The future of nanotechnology in personalized medicine is bright. Promising innovations are on the horizon for redefining standards of care. Real-time monitoring of wearable nanotechnology, gene delivery systems enabled by nanoparticles, and personalized theranostic platforms are promising to redefine the face of disease management and treatment. Translating these advancements will call for critical collaboration among the researchers, clinicians, and regulatory authorities to make it accessible, affordable, and impactful healthcare solutions.

This application of nanotechnology has thus been extended from the domain of potential promise into actual clinical outcome in meeting complexity associated with precision medicine. As such treatments can now be designed and executed to greatest optimality according to their patient-specific profiles, so indeed it sets very important perspectives regarding the future of medicine. Despite these challenges, continued exploration and integration of nanotechnology into personal care will surely bring transformative breakthroughs that propel us closer to the long-term goal of truly individualized medicine.

References

1. Maeda H, Wu J, Sawa T, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271-84.
2. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature Rev Drug Disc. 2008;7:771-82.
3. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nature Rev Drug Disc. 2005;4: 145-60.
4. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nature Rev Clin Onco. 2010;7:653-64.
5. Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology. 2007;2:751-60.
6. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387-92.
7. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Ann Rev Medi. 2012;63:185-98.
8. Sengupta S, Benjamin LE. Nanotechnology for cancer therapy: hype or hope? Nature Medicine. 2007;13:929-35.
9. Alexis F, Pridgen E, Molnar LK, et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Molecu Pharma. 2008;5:505-15.
10. Sun TM, Zhang YS, Pang B, et al. Engineered nanoparticles for drug delivery in cancer therapy. Angewandte Chemie Internat Edi. 2014;53:12320-64.
11. Sykes EA. Tailoring nanoparticles for personalized cancer therapies. Nature Nanotechno. 2014;9:821-3.
12. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nature Rev Cancer. 2005;5:161-71.
13. Torchilin VP. Multifunctional nanocarriers. Advanc Drug Deliv Rev. 2006;58:1532-55.
14. Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proce Nation Acad Sci. 2006;103:6315-20.
15. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Advan Drug Deliv Rev. 2001;46:149-68.
16. Nie S, Xing Y, Kim GJ, et al. Nanotechnology applications in cancer. Annual Rev Biomedical Engg. 2007;9:257-88.
17. Park K, Kang E. Safe and efficient nanocarriers: commentaries on clinical success and remaining issues in nanomedicine. Nano Today. 2010;5:325-30.
18. Kamaly N, Xiao Z, Valencia PM, et al. Targeted polymeric therapeutic nanoparticles: design, development, and clinical translation. Chem Socit Rev. 2012;41:2971-3010.
19. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncogy. 2005;23:7794-803.
20. Petros RA, De Simone JM. Strategies in the design of nanoparticles for therapeutic applications. Nature Rev Drug Discov. 2010;9:615-27.
21. Prajapati RN, Jagrati K, Sengar A, et al. Nanoparticles: pioneering the future of drug delivery and beyond. World J Pharmaceutical Res. 2024;13:1243-62.
22. Sengar A, Jagrati K, Khatri S. Enhancing therapeutics: a comprehensive review on naso-pulmonary drug delivery systems for respiratory health management. World J Pharmaceutical Res. 2024;13:1112-40.
23. Sengar A. Targeting methods: a short review including rationale, goal, causes, strategies for targeting. Intern J Res Publi Rev. 2023;4:1379-84.

24. Jagrati KM, Sengar A. Liposomal vesicular delivery system: an innovative nano carrier. World J Pharma Res. 2024;13:1155-69.

25. Sengar A, Vashisth H, Chatekar VK, et al. From concept to consumption: a comprehensive review of chewable tablets. World J Pharma Res. 2024;13:176-89.

26. Sengar A, Tile SA, Sen A, et al. Effervescent tablets explored: dosage form benefits, formulation strategies, and methodological insights. World J Pharma Res. 2024;13:1424-35.

27. Sengar A, Saha S, Sharma L, et al. Fundamentals of proniosomes: structure & composition, and core principles. World J Pharma Res. 2024;13:1063-71.

28. O'Neal DP, Hirsch LR, Halas NJ, et al. Photo-thermal tumor ablation in mice using near-infrared-absorbing nanoparticles. Cancer Letters. 2004;209:171-6.

29. Gao X, Cui Y, Levenson R, et al. In vivo cancer targeting and imaging with semiconductor quantum dots. Nature Biotech. 2004;22:969-76.

30. Sengar A, Yadav S, Niranjan SK. Formulation and evaluation of mouth-dissolving films of propranolol hydrochloride. World J Pharma Res. 2024;13:850-61.

31. Nishiyama N, Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharma Therape. 2006;112:630-48.

32. Bertrand N, Wu J, Xu X, et al. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Advan Drug Deliv Rev. 2014;66:2-25.

33. Alghamdi MA, Fallica AN, Virzì N, et al. The promise of nanotechnology in personalized medicine. J Person Medi. 2022;12:673.